U.S. Markets closed

Wall Street Transcript Interview with Gregory J. Fluet, the CEO of Urologix, Inc. (ULGX)

67 WALL STREET, New York - March 17, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - End Market Improvement - Biotech, Pharma and Medical Device Convergence - Changing Competitive Dynamics

Companies include: Urologix, Inc. (ULGX) and many more.

In the following excerpt from the Medical Devices Report, the CEO of Urologix, Inc. (ULGX) discusses company strategy and the outlook for this vital industry:

TWST: What is your market penetration for these products in the U.S.? Is this market essentially urologists?

Mr. Fluet: We are looking at urologists. We're currently in approximately 22% of the urology offices in the United States, and so there are still a number of urologists that have not adopted our in-office technologies and are relying predominantly on medication to manage their patients. But as I said before, we have only scratched the surface of the treatable patient population. There are over 4 million men who are on chronic medication now, and almost half report being unsatisfied with their improvement on drugs. For those that are sickest, surgery becomes the default option.

TWST: What do you view as your main competition?

Mr. Fluet: Our main competition is actually drug therapy. One of our challenges is that there is not a lot of current patient awareness about the in-office treatment options that we offer. Almost everybody is aware of Flomax, and some of the other drugs, like Avodart or alpha-blockers, to treat BPH. They've got phenomenal direct-to-consumer - DTC - marketing campaigns. The companies really spent a lot of time and money raising patient awareness. But beyond that, most men think that if they tell their urologists that the drugs aren't working or if they say they want something that gives them a better outcome, their only option in their mind is surgery.

Most men are pretty reticent to kind of volunteer for a surgical procedure, particularly a TURP or a laser TURP procedure, unless they almost have to have that procedure. That is a big mental hurdle. And we found that many men - when they understand that there is an alternative that is a safe, durable and effective option that can be delivered in the comfort of the urologist's own office, that doesn't require general anesthesia, that has a relatively short procedure time and with which they go home the same day, that most patients will be able to get off their chronic drug regimen for BPH - there is a lot of interest in that, and our challenge is just to be able to educate more patients on those treatment options we offer.

TWST: Are you selling internationally?

Mr. Fluet: We sell Prostiva to...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.